Evidence map›Paper›PMID 23563512›Full record

ArticleHuman vaccines & immunotherapeutics2013

Effect of single-point mutations on the stability and immunogenicity of a recombinant ricin A chain subunit vaccine antigen.

Justin C Thomas, Joanne M O'Hara, Lei Hu, Fei P Gao, Sangeeta B Joshi, David B Volkin, Robert N Brey, Jianwen Fang, John Karanicolas, Nicholas J Mantis and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Justin C ThomasMacromolecule and Vaccine Stabilization Center; Department of Pharmaceutical Chemistry; University of Kansas; Lawrence, KS USA.
Joanne M O'Hara
Lei Hu
Fei P Gao
Sangeeta B Joshi
David B Volkin
Robert N Brey
Jianwen Fang
John Karanicolas
Nicholas J Mantis
C Russell Middaugh
University of Kansas · USNew York State Department of Health · USCore Laboratories (United States) · US

Funding

TRAFFICKING OF THE PLASMA MEMBRANE CA2+-ATPASE TO RAFTSP20RR017708 · NCRR · UNIVERSITY OF KANSAS LAWRENCE · PI FISCHER, CHRISTOPHER JAMES · 2002 to 2011
$20.1M
Development of stable and rapidly acting adjuvanted vaccines for biodefenseU01AI082210 · NIAID · SOLIGENIX, INC. · PI BREY, ROBERT N. · 2009 to 2013
$9.1M
PHARMACEUTICAL ASPECTS OF BIOTECHNOLOGY TRAININGT32GM008359 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI SIAHAAN, TERUNA J., VOLKIN, DAVID · 1989 to 2018
$5.0M
NCRR NIH HHS P20 RR017708NIAID NIH HHS U01 AI082210NIAID NIH HHS U01AI082210NIGMS NIH HHS T32 GM008359NIGMS NIH HHS T32-GM008359
6 · The paper itself

Abstract

There is great interest in the design and development of highly thermostable and immunogenic protein subunit vaccines for biodefense. In this study, we used two orthogonal and complementary computational protein design approaches to generate a series of single-point mutants of RiVax, an attenuated recombinant ricin A chain (RTA) protein subunit vaccine antigen. As assessed by differential scanning calorimetry, the conformational stabilities of the designed mutants ranged from 4°C less stable to 4.5°C more stable than RiVax, depending on solution pH. Two more thermostable (V18P, C171L) and two less thermostable (T13V, S89T) mutants that displayed native-like secondary and tertiary structures (as determined by circular dichroism and fluorescence spectral analysis, respectively) were tested for their capacity to elicit RTA-specific antibodies and toxin-neutralizing activity. Following a prime-boost regimen, we found qualitative differences with respect to specific antibody titers and toxin neutralizing antibody levels induced by the different mutants. Upon a second boost with the more thermostable mutant C171L, a statistically significant increase in RTA-specific antibody titers was observed when compared with RiVax-immunized mice. Notably, the results indicate that single residue changes can be made to the RiVax antigen that increase its thermal stability without adversely impacting the efficacy of the vaccine.

Indexed as

Point MutationAnimalsAntibodies, NeutralizingAntitoxinsBlood GlucoseCalorimetryCircular DichroismDisease Models, AnimalDrug StabilityMiceMice, Inbred BALB CMutant ProteinsPoisoningProtein ConformationProtein StabilityRicinAntibodies, NeutralizingAntitoxinsBlood GlucoseMutant ProteinsRicinVaccines, SubunitVaccines, Syntheticantigencomputational protein designimmunogenicityprotein stabilityricinvaccine

Identifiers

PMID23563512
PMCPMC3903890
OpenAlexW1971046807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.